Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can remote glucose monitoring tame type 2 diabetes in underserved communities?

NCT ID NCT06939413

Disease control Sponsor: Diabetes Solutions International Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 17, 2026 · Last updated Aug 18, 2026 · Updated 1 time

Summary

This study tests whether a diabetes care program using continuous glucose monitors (CGM) and remote patient monitoring can help adults with uncontrolled type 2 diabetes improve their blood sugar levels and reduce diabetes-related distress. Participants will wear a CGM that shows how their glucose responds to food, activity, and medication, while their care team remotely monitors the data and adjusts treatment as needed. The trial will measure changes in A1c, time in range, and diabetes distress over 52 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Continuous glucose monitor (CGM) and remote patient monitoring (RPM)
What this could lead to
If successful, this program could offer a practical, sustainable way to improve blood sugar control and reduce diabetes-related distress in underserved communities.
What could go wrong
This is a small, early-stage study (40 participants) without a control group, so results may not be generalizable. The intervention relies on patient engagement and clinic resources, which may limit its real-world impact.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2025

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults 18 years or older with Type 2 diabetes AND * A1c \> 8% Exclusion Criteria: * Pregnancy (participant-reported) * Previous real time CGM use for more than 6 weeks in the last 3 months * Use of steroids * Active cancer treatment * Terminal illness * Dementia, mental impairment * Type 1 diabetes * End stage renal disease, on dialysis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 2 diabetes mellitus (T2DM) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Type 2 diabetes mellitus (T2DM)

Contacts and locations

Locations

  • Community Health Center of Franklin County

    Greenfield, Massachusetts, 01301, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.